ArticleJournal of general and family medicine2026
COVID-19 as a Potential Trigger for Tuberculosis: Insights From a Large-Scale Japanese Insurance Database Analysis.
Article in Journal of general and family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The long-term impact of COVID-19 on tuberculosis (TB) is concerning. This study assessed whether COVID-19 was associated with an increased risk of active TB treatment risk in Japan using a nationwide propensity score-matched cohort design. Methods: A retrospective cohort study used Japan's National Insurance Database from January 2020 to December 2022. COVID-19 patients were matched 1:1 with controls using propensity scores based on age, sex, immunosuppressants use, Charlson comorbidity index, related medical conditions, healthcare utilization and prior TB history. The primary outcome was initiation of isoniazid-based therapy plus rifampin with a TB-related ICD-10 diagnosis code. Cox proportional hazards models estimated hazard ratios (HRs) for COVID-19's effect on TB treatment initiation. Results: After matching, 3,097,422 individuals were included per group. During 8-month median follow-up, 886 participants initiated TB treatment. The HR among COVID-19 infected individuals was 4.14 (95% CI: 3.51-4.89) versus matched controls. Subgroup analyses showed interaction between prior TB history and COVID-19, with HR of 14.7 (5.35-40.2) in those with prior TB history, versus those without (HR 3.84, 95% CI 3.24-4.54). Risk remained elevated in participants without hospitalization (HR 3.96, 95% CI 3.35-4.68). Conclusions: This study provides robust population-based evidence demonstrating a moderate association between prior COVID-19 and subsequent initiation of active tuberculosis treatment, particularly in those with prior TB history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.